IBD Research Resource Center

Clinical ID	c3242
Identifier	ACTRN12611000363987
Trial Title	The Triple A (Adjunctive Allopurinol and Azathioprine) Study: Use of Ajunctive Allopurinol in Azathioprine/6-Mercaptopurine Non-responders to Optimize 6-Thioguanine Nucleotide Production and Improve Clinical Outcomes in Patients with Inflammatory Bowel Disease (IBD).
Trial URL	Visit Original Page

Study Results	No results available
Conditions	Inflammatory Bowel Disease (IBD); Inflammatory Bowel Disease (IBD);Oral and Gastrointestinal - Inflammatory bowel disease;Inflammatory and Immune System - Other inflammatory or immune system disorders
Interventions	Eligible IBD patients will be randomly allocated to receive either 100mg or 50mg of allopurinol orally in 1:1 using computer generated list. Patients will continue to take their usual azathioprine or 6-mercaptopurine at reduced doses as determined by the study doctor. The study duration for each individual patient is 24 weeks. Allopurinol will be taken once dail and frequency for usual azathioprine or 6-mercaptopurine treatments remains regular.

Sex Requirement	ALL
Age Requirement	ADULT, OLDER_ADULT

Study Type	Interventional
Phase	PHASE3\|PHASE4